In vitro activities of T-3262, NY-198, fleroxacin (AM-833; RO 23-6240), and other new quinolone agents against clinically isolated Chlamydia trachomatis strains.
The in vitro activities of three newly developed quinolone drugs (T-3262, NY-198, and fleroxacin [AM-833; RO 23-6240]) against 10 strains of clinically isolated Chlamydia trachomatis were assessed and compared with those of other quinolones and minocycline. T-3262 (MIC for 90% of isolates tested, 0.1 microgram/ml) was the most active of the quinolones. The NY-198 and fleroxacin MICs for 90% of isolates were 3.13 and 62.5 micrograms/ml, respectively.
Maeda
H
H
Department of Urology, School of Medicine, Kobe University, Japan.
Fujii
A
A
Nakata
K
K
Arakawa
S
S
Kamidono
S
S
D000890:Anti-Infective Agents / Q000494:pharmacology; D002689:Chlamydia / Q000187:drug effects*; D002939:Ciprofloxacin / Q000031:analogs & derivatives / Q000494:pharmacology; D016576:Fleroxacin; D024841:Fluoroquinolones; D009287:Naphthyridines; D015363:Quinolones / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D015363:Quinolones; D002939:Ciprofloxacin; C055185:tosufloxacin; C053091:lomefloxacin; D016576:Fleroxacin